• In March 2026, Liquidia Corporation reported fourth-quarter 2025 revenue of US$92.02 million versus US$2.92 million a year earlier, shifting from a net loss to net income of US$14.56 million and delivering positive earnings per share from continuing operations.
• For 2025 as a whole, revenue rose to US$158.32 million while the annual net loss narrowed to US$68.92 million, and on the same day Liquidia filed multiple shelf registrations covering common and preferred stock, debt securities, warrants, units and employee share offerings, signalling preparation for potential future capital needs.
• We’ll now examine how Liquidia’s move to quarterly profitability and fresh shelf registrations could influence its existing investment narrative.

Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.

Liquidia Investment Narrative Recap

To own Liquidia, you need to believe YUTREPIA can sustain meaningful prescription and revenue traction while the company manages concentration and legal risks around its treprostinil franchise. The shift to quarterly profitability in Q4 2025 strengthens the near term catalyst around YUTREPIA execution, but it does not remove the key risk that payer terms, treatment patterns or competitive data could blunt the translation of early uptake into durable earnings.

The new omnibus and ESOP related shelf registrations, filed alongside the strong Q4 numbers, are the most relevant announcements here because they frame how Liquidia might fund its expanding manufacturing footprint and pipeline work around L606. They sit in the background of the main catalysts such as growing YUTREPIA use, improving payer access and planned capacity expansion, and may shape how existing shareholders think about future dilution relative to potential operating leverage.

Yet behind the strong quarter, investors should still be aware of how payer coverage and rebate terms could limit how much of YUTREPIA’s prescription growth actually turns into...

Liquidia's narrative projects $717.7 million revenue and $299.9 million earnings by 2029. This requires 118.1% yearly revenue growth and an earnings increase of about $424 million from -$124.1 million today.

Uncover how Liquidia's forecasts yield a $44.00 fair value, a 19% upside to its current price.

Exploring Other Perspectives

While Q4’s US$92.02 million revenue and first quarterly profit may look encouraging, some analysts previously expected only US$555.6 million revenue and modest earnings by 2028, highlighting how cautious views on YUTREPIA’s staying power and litigation risk can differ sharply from more optimistic assumptions.

Explore 5 other fair value estimates on Liquidia - why the stock might be worth less than half the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Liquidia research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Liquidia research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Liquidia's overall financial health at a glance.

Curious About Other Options?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.